Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma

Бойко, Н. В.; Lodochkina, O.E.; Kit, M M; Kuleshova, V G; Nedashkovskaya, N G

doi:10.17116/otorino20218602143

Cited by 7 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of them demonstrated that different anti-IL-5 biologics promoted improvement compared to the placebo arm in various evaluated parameters, including quality of life, nasal obstruction, the need for systemic corticosteroid use to relieve nasal symptoms, olfaction, polyp size, opacification on computed tomography and the need for polyp surgery. 57 , 58 , 59 In fact, only Benralizumab and Mepolizumab were analyzed for this purpose. In addition, several studies primarily evaluating asthma showed that patients obtained significant improvements in upper airway outcomes with all three options blocking IL-5.…”

Section: In Chronic Rhinosinusitismentioning

confidence: 99%

Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update

Anselmo-Lima,

Romano,

Tamashiro

et al. 2024

Brazilian Journal of Otorhinolaryngology

View full text Add to dashboard Cite

Section: In Chronic Rhinosinusitismentioning

confidence: 99%

Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update

Anselmo-Lima,

Romano,

Tamashiro

et al. 2024

Brazilian Journal of Otorhinolaryngology

View full text Add to dashboard Cite

“…The correlation between the severity of CRSwNP and eosinophilic asthma, the proximity of the endotypes of these diseases [16] along with the successful use of biologics for the treatment of severe asthma [14] explain the interest in the research of the possibility of using this group of drugs in patients with CRSwNP [17], [18], [19], [20].…”

Section: Introductionmentioning

confidence: 99%

Chronic Rhinosinusitis with Polyps and Comorbid Asthma: Results of Reslizumab Treatment

Бойко¹,

Stagnieva²,

Lodochkina³

2023

SEE J Immunol

View full text Add to dashboard Cite

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are comorbid, mutually burdening, difficult-to-treat diseases. The presence of a correlation between the severity of the course of CRSwNP and eosinophilic asthma, the proximity of the endotypes of these diseases, and the success in the application of humanized monoclonal antibodies for the treatment of severe asthma explain the interest in the study of the possibility of using this group of medications in patients with CRSwNP. AIM: The present study purposes to evaluate changes in the severity of CRS symptoms in patients with comorbid asthma during reslizumab treatment. The clinical effect of the treatment, the dynamics of subjective and objective characteristics of (CRSwNP) and asthma symptoms, indicators of general and local eosinophilia have been analyzed. MATERIALS AND METHODS: The study involved 18 patients with severe eosinophilic asthma, treated with reslizumab. Research protocol: the first examination conducted before reslizumab treatment included an assessment of clinical symptoms using Sino-nasal outcome test-22 and asthma control test, endoscopic examination of the nasal cavity, computed tomography of the paranasal sinuses, rhinocytogram, determination of the content of eosinophils and eosinophil cation protein in the blood, spirometry. Evaluation of the results of treatment was carried out after 6 injections of reslizumab at a dose of 3 mg/kg 1 time every 4 weeks. The obtained data were processed by means of the “Statistica 12.0” program (StatSoft, USA). The differences in the indicators were considered statistically significant at p < 0.05. RESULTS: After 6 injections of reslizumab both a noticeable improvement in asthma control and a decrease in the severity of the nasal symptoms were noted. A more evident effect in diminution of asthma symptoms due to the use of reslizumab was obtained in patients with severe eosinophilic asthma with CRSwNP compared with cases without polyps. CONCLUSION: Treatment with reslizumab in patients with eosinophilic asthma and concomitant CRS with polyps and eosinophilic CRS leads not only to improved control of asthma symptoms but also to significant regression of nasal symptoms.

show abstract

Novel therapeutic approaches targeting endotypes of severe airway disease

Filippo

Votto

Licari

et al. 2021

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma

Cited by 7 publications

References 28 publications

Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update

Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update

Chronic Rhinosinusitis with Polyps and Comorbid Asthma: Results of Reslizumab Treatment

Novel therapeutic approaches targeting endotypes of severe airway disease

Contact Info

Product

Resources

About